MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash

Reuters

2025/08/25

MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash

MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with Blackstone, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186994), on August 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562246540"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562246540\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562246540?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562246540","market":"fut","top_or_hot":-1,"title":"MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with <a href=\"https://laohu8.com/S/BX\">Blackstone</a>, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186994), on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-25 19:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with <a href=\"https://laohu8.com/S/BX\">Blackstone</a>, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186994), on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCPH","symbol_name":"Scpharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDLb8Y4mv:1","article_id":"2562246540","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562246540","pubTimestamp":1756121644,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with Blackstone, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCPH":"Scpharmaceuticals Inc.","BK4139":"生物科技","MNKD":"曼恩凯德生物医疗","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"MannKind Corporation宣布达成最终协议，以每股5.35美元现金收购scPharmaceuticals","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCPH":0.9,"MNKD":0.9},"content_text":"MannKind Corporation Announces Definitive Agreement to Acquire scPharmaceuticals for $5.35 Per Share in Cash\n    \n\n        MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with Blackstone, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186994), on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}